Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Wockhardt Ltd. Share Price
Day's Range
Day's Range
Low
₹1,966.10
High
₹2,028.00
Price Summary
| Previous Close | ₹2,021.00 |
|---|---|
| Day's Range | ₹1,966.10 - ₹2,028.00 |
| Open | ₹1,966.10 |
| 52 Week Range | ₹1,086.70 - ₹2,422.30 |
| Volume | 5,46,004 |
| Market Cap | ₹0.03 |
| Previous Close | ₹2,020.70 |
|---|---|
| Day's Range | ₹1,970.00 - ₹2,026.75 |
| Open | ₹1,972.10 |
| 52 Week Range | ₹1,086.80 - ₹2,420.00 |
| Volume | 36,727 |
| Market Cap | ₹0.03 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 11,034.74 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 150.51 |
| TTM EPS (₹) | 13.11 |
| P/E Ratio | 89.54 |
| Book Value(₹) | 6.51 |
| PAT Margin (%) | 5.13 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 6.79 |
| Trade Value ( ₹ in Lacs) | 742.14 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 150.51 |
| TTM EPS (₹) | 13.11 |
| P/E Ratio | 89.54 |
| Book Value(₹) | 6.51 |
| PAT Margin (%) | 5.13 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 6.79 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 7430.0 | 30120.0 |
| Expenses | N/A | N/A |
| PBT | -220.0 | -160.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -450.0 | -570.0 |
About Wockhardt Ltd.
| Founded | 1999 |
|---|---|
| Managing Director | Murtaza Khorakiwala |
| NSE Symbol | WOCKPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,66,430.72 | 1,949.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,20,114.60 | 8,248.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,88,852.64 | 4,952.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,715.98 | 8,980.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,19,158.34 | 1,472.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,10,348.86 | 1,115.20 | 835.50 - 835.50 |
| Lupin Ltd. | 1,09,347.72 | 2,360.00 | 1,855.00 - 1,855.00 |
| Max Healthcare Institute Ltd. | 1,04,626.89 | 1,073.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,00,395.19 | 2,439.00 | 1,909.70 - 1,909.70 |
| Laurus Labs Ltd. | 99,201.32 | 1,855.00 | 810.05 - 810.05 |
No Records Found
Latest News
Wockhardt informs about certificate
Blue Jet Healthcare informs about transcript of earnings call
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, Blue Jet Healthcare has informed that it enclosed the transcript of the Earnings Call with the Analysts/ Investors on the Financial Results for the quarter ended June 30, 2026 held on August 03, 2026. The same is also available at: https://bluejethealthcare.com/investor-presentation.
The above information is a part of company’s filings submitted to BSE.
Lupin informs about revised investor presentation
Krsnaa Diagnostics informs about board meeting
Pursuant to the provisions of Regulation 29(1) & (2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Krsnaa Diagnostics has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, August 13, 2026 - to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2026. - to consider and evaluate the proposal for raising of funds by way of issuance of one or more instrument(s) / securities which may include equity shares, fully convertible warrants and/or any other eligible securities (convertible / non-convertible) and / or any combinations of securities thereof through permissible modes, including but not limited to a preferential issue on a private placement basis or through any other permissible mode and / or combination thereof as may be considered appropriate, in accordance with the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, as amended, to the promoter/promoter group, subject to all such shareholders’, regulatory / statutory and other applicable approvals, if any, as may be required including conducting shareholders meeting. Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall continue to remain closed until August 15, 2026. This intimation is also being uploaded on the Company’s website at https://krsnaadiagnostics.com/investors/.
The above information is a part of company’s filings submitted to BSE.
Suven Life Sciences - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 35.66 | 18.67 | 91.00 | 35.66 | 18.67 | 91.00 | 71.15 | 66.56 | 6.90 |
| Other Income | 75.24 | 5.89 | 1177.42 | 75.24 | 5.89 | 1177.42 | 139.10 | 107.26 | 29.68 |
| PBIDT | -134.89 | -134.10 | 0.59 | -134.89 | -134.10 | 0.59 | -490.91 | -412.11 | 19.12 |
| Interest | 4.76 | 0.00 | 0.00 | 4.76 | 0.00 | 0.00 | 1.58 | 0.47 | 236.17 |
| PBDT | -139.65 | -134.10 | 4.14 | -139.65 | -134.10 | 4.14 | -492.49 | -412.58 | 19.37 |
| Depreciation | 21.55 | 13.68 | 57.53 | 21.55 | 13.68 | 57.53 | 56.14 | 58.22 | -3.57 |
| PBT | -161.20 | -147.78 | 9.08 | -161.20 | -147.78 | 9.08 | -548.63 | -470.80 | 16.53 |
| TAX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | -161.20 | -147.78 | 9.08 | -161.20 | -147.78 | 9.08 | -548.63 | -470.80 | 16.53 |
| Equity | 263.99 | 218.07 | 21.06 | 263.99 | 218.07 | 21.06 | 263.72 | 218.07 | 20.93 |
| PBIDTM(%) | -378.27 | -718.26 | -47.34 | -378.27 | -718.26 | -47.34 | -689.96 | -619.16 | 11.44 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Wockhardt Ltd. is ₹2,021.00 as of 2026-08-07.
The market capitalisation of Wockhardt Ltd. is ₹32,059.70 as of 2026-08-06.
The 1-year return of Wockhardt Ltd. is 543.80% as of 2026-08-07.
The P/E ratio of Wockhardt Ltd. is 89.54 as of 2026-08-07.
The 52-week high and low of Wockhardt Ltd. are ₹2,422.30 and ₹1,086.70, respectively, as of 2026-08-07.
People Also Ask
Wockhardt Ltd. offers branded generics, biopharmaceuticals and novel antibiotics in areas like cardiology, diabetology, gastroenterology and infectious diseases, with operations across India, the UK and emerging markets.
Wockhardt Ltd. partners through hospital‑focused product portfolios, licensing, contract manufacturing and supplying critical‑care and acute‑care drugs in multiple geographies.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
